Aug 12, 2026 07:30AM
Aug 3, 2026 08:01AM
Aug 3, 2026 08:00AM
Jul 29, 2026 06:53AM
Jul 28, 2026 07:00AM
Jul 28, 2026 07:00AM
May 28, 2026 11:00AM Altimmune reports metabolic improvements for MASH drug pemvidutide
May 28, 2026 11:00AM
May 27, 2026 08:01AM
May 27, 2026 08:00AM
May 19, 2026 06:48AM
May 13, 2026 08:30AM
May 13, 2026 07:30AM
May 13, 2026 07:15AM Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
Mar 27, 2026 10:53AM
Mar 17, 2026 06:46AM
Mar 5, 2026 11:31AM
Mar 5, 2026 07:00AM
Jan 29, 2026 05:54PM
Jan 29, 2026 05:54PM
Jan 27, 2026 09:25PM Altimmune prices $75 million stock offering to fund MASH trial
Jan 27, 2026 09:25PM
Jan 27, 2026 06:32AM
Jan 5, 2026 07:31AM
Jan 5, 2026 07:30AM
Dec 19, 2025 06:30AM
Dec 19, 2025 06:30AM
Dec 1, 2025 07:31AM Altimmune names Jerry Durso as new CEO effective January 2026
Dec 1, 2025 07:30AM
Nov 12, 2025 04:47AM
Nov 11, 2025 08:52AM
Nov 11, 2025 08:51AM
Nov 7, 2025 08:06AM
Nov 7, 2025 08:05AM
Nov 6, 2025 07:00AM Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
Nov 3, 2025 07:30AM
Nov 3, 2025 07:30AM
Oct 20, 2025 07:30AM
Sep 29, 2025 07:30AM
Sep 29, 2025 07:30AM
Aug 19, 2025 07:30AM
Aug 19, 2025 07:30AM Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
Aug 12, 2025 07:00AM
Aug 11, 2025 07:30AM
Aug 11, 2025 07:30AM
Jul 9, 2025 07:30AM
Jul 9, 2025 07:30AM
Jun 26, 2025 07:02AM
Jun 26, 2025 07:00AM Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
Jun 25, 2025 07:12PM

329,911 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All